Dr. McAllister is the co-founder and CEO of Cytograft Tissue Engineering, Inc., a regenerative medicine company developing cell-based therapies to repair and rebuild diseased tissues and organs without using synthetic biomaterials. He has a B.S degree in Mechanical Engineering from the University of Washington, and a Ph.D. in Biomedical Engineering from the University of California, San Diego. Dr. McAllister pioneered a novel business strategy that prioritized capital efficiency and research focus. Over the span of 6 years, Cytograft was able to transition from inception to Phase II clinical trials, and is moving programs forward based on its proprietary platform, “TESA™,” Tissue Engineering by Self Assembly™. Cytograft is now one of the few Regenerative Medicine companies pursuing Phase IIb/III clinical trials. The Company has a broad platform of therapeutic indications with vascular grafts, valve leaflets, covered stents, and dermal fillers that are under development.
With more than two decades of experience, Dr. McAllister is a well-known thought leader in the field of Regenerative Medicine. He is a frequent reviewer and contributor for high impact journals and is on the editorial board of the Journal of Biofabrication and on the Industry Committee for the Journal of Tissue Engineering. He is on the Executive Board for the International Cell Medicine Society. Dr. McAllister has also sat as a reviewer or external advisory board member for AFIRM, NIH, and NSF EPSCOR grants. He has sat on the advisory boards of several companies, including BioCardia, Lumen Therapeutics, Wolf Biosciences and others. Dr. McAllister’s was also the co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, Georgia, where he oversaw a broader range of cell-based repair technologies.